Analysts Have Been Trimming Their Eris Lifesciences Limited (NSE:ERIS) Price Target After Its Latest Report
It's been a good week for Eris Lifesciences Limited (NSE:ERIS) shareholders, because the company has just released its latest quarterly results, and the shares gained 5.6% to ₹1,156. Eris Lifesciences reported in line with analyst predictions, delivering revenues of ₹8.9b and statutory earnings per share of ₹45.26, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
After the latest results, the ten analysts covering Eris Lifesciences are now predicting revenues of ₹35.1b in 2027. If met, this would reflect a modest 5.8% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to sink 13% to ₹44.54 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹35.2b and earnings per share (EPS) of ₹43.67 in 2027. So the consensus seems to have become somewhat more optimistic on Eris Lifesciences' earnings potential following these results.
Check out our latest analysis for Eris Lifesciences
The consensus price target fell 7.2% to ₹1,514, suggesting the increase in earnings forecasts was not enough to offset other the analysts concerns. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Eris Lifesciences at ₹1,780 per share, while the most bearish prices it at ₹1,140. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Eris Lifesciences' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Eris Lifesciences' revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 12% growth on an annualised basis. This is compared to a historical growth rate of 21% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 12% annually. So it's pretty clear that, while Eris Lifesciences' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Eris Lifesciences following these results. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Eris Lifesciences going out to 2029, and you can see them free on our platform here..
Plus, you should also learn about the 2 warning signs we've spotted with Eris Lifesciences .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.